A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2006
11/02/2006	US20060247311 Using synergistic mixture of 1-(aminomethyl)-cyclohexane acetic acid or (1-aminomethyl-3,4-dimethylcyclopentyl)acetic acid and smooth muscle moderator including antimuscarinic agent Tolterodine
11/02/2006	US20060247310 Body temperature elevating agents
11/02/2006	US20060247284 Use of 7-nitro-2,1,3 benzoxadiazole derivatives for anticancer therapy
11/02/2006	US20060247275 Treating hyperproliferative disorders such as gastrointestinal cancer, breast cancer, head cancer, or neck cancer; N-(4-trifluoromethoxyphenyl) 3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide
11/02/2006	US20060247257 Combination
11/02/2006	US20060247252 Augmented cognitive training
11/02/2006	US20060247216 Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
11/02/2006	US20060247199 Methods and products for manipulating uncoupling protein expression
11/02/2006	US20060247186 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
11/02/2006	US20060247161 Use of active ingredients for the prophylaxis and/or therapy of viral diseases
11/02/2006	US20060246587 Methods for transfecting T cells
11/02/2006	US20060246525 Method of screening remedy for heart disease and medicinal composition for treating heart disease
11/02/2006	US20060246486 Human signal peptide-containing proteins
11/02/2006	US20060246147 Supplement preparation
11/02/2006	US20060246130 Compositions and methods for combination antiviral therapy
11/02/2006	US20060246085 Methods for manipulating satiety
11/02/2006	US20060246061 Method for generating monoclonal antibodies
11/02/2006	US20060246055 Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
11/02/2006	US20060246053 Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or "novel acting thrombolytic agent" (NAT) with buffer of sodium citrate, zinc acetate, and/or calcium acetate; regeneration
11/02/2006	US20060246046 Modified tridegins, production and use thereof as transglutaminase inihibitors
11/02/2006	US20060246045 Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concertration
11/02/2006	US20060246039 Growth differentiation factor-7
11/02/2006	US20060246036 Delivery of therapeutics to the brain and spinal cord
11/02/2006	US20060246012 Delivery of physiologically active compounds through an inhalation route
11/02/2006	US20060246011 Delivery of diphenhydramine through an inhalation route
11/02/2006	US20060243276 Methods for treating rhinitis and conjunctivitis
11/02/2006	EP1717310A1 Lineage-directed induction of human mesenchymal stem cell differentiation
11/02/2006	EP1717230A1 Fused-ring 4-oxopyrimidine derivative
11/02/2006	EP1717224A1 Peptidyl arginine deiminase type iv inhibitor
11/02/2006	EP1716875A2 Container unit for dialysate concentrate
11/02/2006	EP1716869A1 Drug for preventing or treating heart diseases comprising cd9 gene
11/02/2006	EP1716868A1 Anti-inflammatory analgesic for external use
11/02/2006	EP1716867A1 Preventives for migraine
11/02/2006	EP1716861A2 Inhibitors of proteasomal activity for stimulating bone and hair growth
11/02/2006	EP1716156A2 Chemokine ccr5 receptor modulators
11/02/2006	EP1715971A1 Functionalized colloidal metal compositions and methods
11/02/2006	EP1715896A1 Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
11/02/2006	EP1715864A1 Use of siramesine in the treatment of cancer
11/02/2006	EP1715863A2 Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
11/02/2006	EP1715843A1 Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
11/02/2006	EP1517682B1 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
11/02/2006	EP1501565B1 Compounds and method for coating surfaces in a haemocompatible manner
11/02/2006	EP1485040B1 Method of administering an injectable antibiotic to the ear of an animal
11/02/2006	EP1467761B1 Treatment of neovascular ophthalmic disease
11/02/2006	EP1387689B1 Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
11/02/2006	EP1377278B1 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
11/02/2006	EP1337243B1 Delayed-release pharmaceutical formulations containing proinsulin c-peptide
11/02/2006	EP1322351B1 Coated medical devices
11/02/2006	EP1278525B1 Pyrophosphates for enhancing cellular function through protection of muscarinic receptors
11/02/2006	EP1223925B1 Fatty acid derivative for the treatment of external secretion disorders
11/02/2006	EP1102604B1 Drug releasing elastic band
11/02/2006	EP1102589B1 Topical compositions comprising an opioid analgesic and an nmda antagonist
11/02/2006	EP0973534B1 Plant extracts having appetite suppressant activity
11/02/2006	EP0873361B1 Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
11/02/2006	EP0854722B1 Proteins involved in targeting of peptidyl transfer center, and corresponding therapeutic agents and methods
11/02/2006	EP0719331B1 Eotaxin = eosinophil chemotactic cytokine
11/02/2006	DE102005020798A1 Pharmaceutical for treatment of central nervous system diseases, comprises toll-like receptor ligand and/or Nod2 ligand
11/02/2006	CA2606239A1 Preventive or remedy for bowel disease
11/02/2006	CA2606083A1 Method for evaluating compound using barlp and substance for regulating eating and body weight
11/02/2006	CA2606025A1 Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
11/02/2006	CA2605783A1 Matrix metalloproteinase inhibitors of tgf .beta.-induced subcapsular cataract formation
11/02/2006	CA2605447A1 Therapeutic combinations for the treatment or prevention of psychotic disorders
11/02/2006	CA2605365A1 Remedy for xanthoma
11/02/2006	CA2605302A1 Combined pharmaceutical preparation for treatment of type 2 diabetes
11/02/2006	CA2605275A1 Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia
11/02/2006	CA2604856A1 Dermal fillers for biomedical applications in mammals and methods of using the same
11/02/2006	CA2571710A1 Small molecule immunopotentiators and assays for their detection
11/01/2006	CN1856709A Method of predicting spot formation on the skin with the use of spot site-accelerating genes as indication and method of screening inhibitor for spot formation on the skin
11/01/2006	CN1856504A Anti-infarction molecules
11/01/2006	CN1856464A 氨基链烷醇衍生物 Amino alkanol derivative
11/01/2006	CN1856339A Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
11/01/2006	CN1856327A Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
11/01/2006	CN1856326A Combinations of a VEGF receptor inhibitor with other therapeutic agents
11/01/2006	CN1856314A Farmaceutiske kombinationer af adenosin A-2a- og beta-2-adrenerge receptoragonister
11/01/2006	CN1856312A Combination of mGluR2 antagonist and AChE inhibitor for treatment of acute and/or chronic neurological disorders
11/01/2006	CN1856303A Compositions for the treatment and prevention of diabetes mellitus
11/01/2006	CN1856302A Pharmaceutical formulations of xanthogenates and inhibitors of viral nucleic acid replication (e.g. aciclovir)
11/01/2006	CN1854157A Antibodies to insulin-like growth factor i receptor
11/01/2006	CN1853730A Modified cytokines for use in cancer therapy
11/01/2006	CN1853728A Method prescription and use for improving medicine or nutrient oral absorption
11/01/2006	CN1853724A Compound injection with probenecid, potassium and beta-lactam antibiotic and its use
11/01/2006	CN1853723A Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
11/01/2006	CN1853722A Methods for preventing antipsychotic-induced weight gain
11/01/2006	CN1853645A Combined preparations comprising morpholine anthracyclines and anticancer agent
11/01/2006	CN1853642A Combined preparations comprising morpholine anthracyclines and anticancer agent
11/01/2006	CN1853613A Crease-proofing biological preparation, its production and use
11/01/2006	CN1282487C Sustained release medicine for artificially inducing sex reversal of grouper and its preparation method
11/01/2006	CN1282485C Dendron shaped cell tumour vaccine for loading withered heat shock tumour cell, its preparation method and application
11/01/2006	CN1282456C Paroxetine control-released composite
10/2006
10/31/2006	US7129368 Platinum carboxylate anticancer compounds
10/31/2006	US7129332 Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
10/31/2006	US7129251 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
10/31/2006	US7129250 Neuroprotective and anti-proliferative compounds
10/31/2006	US7129242 Such as 4-((4-chlorophenyl)pyrimidin-2-yl)amino)benzamide; for treatment of inflammation/autoimmune conditions
10/31/2006	US7129241 Pyridazine derivatives
10/31/2006	US7129236 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis
10/31/2006	US7129225 Administering an effective amount of a protein tyrosine kinase inhibitor (containing first and second module) to the patient to protect against or to treat hearing loss
10/31/2006	US7129203 Deleting at least one amino acid residue on the protein, and contacting the protein with polyethylene glycol under conditions sufficient to conjugate the polyethylene glycol to the protein
10/31/2006	US7129077 Gene expression inhibition; solid phase synthesis; drug screening; for treating cancer, central nervous system disorders, and chronic obstructive pulmonary disorder
10/31/2006	US7129073 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways

1 ... 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 ... 1151